New mRNA vaccine targets brain infection in global trial
NCT ID NCT06680128
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two new mRNA vaccines (GBP560) against Japanese encephalitis, a virus that can cause brain swelling. About 402 healthy adults will receive different doses of the vaccine or a comparison vaccine. Researchers will monitor safety and measure immune responses to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA vaccine (GBP560) against Japanese encephalitis
What this could lead to
If successful, this could lead to a new, more effective mRNA-based vaccine to prevent Japanese encephalitis, a serious brain infection.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 402 participants. The vaccine may not produce a strong enough immune response or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JAPANESE ENCEPHALITIS VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Clinical Research
NOT_YET_RECRUITINGChristchurch, Central City, 8011, New Zealand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nucleus Network - Brisbane (Q Pharm)
RECRUITINGBrisbane, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nucleus Network - Melbourne
RECRUITINGMelbourne, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••